• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

What is the Risk for Recurrent VTE after Stopping Anticoagulation Treatment?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Data is unclear regarding the ideal time point to discontinue anticoagulation treatment after unprovoked venous thromboembolism (VTE)
    • Discontinuation after 3-6 months vs treating indefinitely
    • Previous meta-analysis did not address male vs female | Follow-up only up to 2 years
  • In patients with first episode unprovoked DVT, Kahn et al. (BMJ, 2019) studied
    • The rate of a first recurrent VTE event after anticoagulation treatment was stopped
    • The total incidence for recurrent VTE up to 10 years

METHODS:

  • Systematic review and meta-analysis
  • Inclusion criteria
    • RCTs and prospective cohort studies
    • Patients were those with first unprovoked VTE at least three months of treatment
    • VTE included both DVT and PE
  • Data extraction and synthesis
    • Two investigators independently screened potential studies, extracted data, and appraised risk of bias
      • Data clarifications were sought from authors of eligible studies
      • Data pooled using random effects meta-analysis
    • Sex and site of initial VTE were also investigated

RESULTS:

  • 18 studies | 7515 patients
  • After discontinuation of anticoagulation treatment: Pooled rate of recurrent VTE per 100 person years
    • First year: 10.3 events (95% confidence interval 8.6 to 12.1)
    • Second year: 6.3 events (5.1 to 7.7)
    • Years 3-5: 3.8 events/year (3.2 to 4.5)
    • Years 6-10: 3.1 events/year (1.7 to 4.9)
  • Cumulative incidence for recurrent VTE was
    • At 2 years: 16% (95% CI, 13% to 19%)
    • At 5 years: 25% (95% CI, 21% to 29%)
    • At 10 years: 36% (95:% CI, 28% to 45%)
  • Women vs men
    • Pooled rate of recurrent VTE per 100 person years in the first year
      • Women: 8.9 events (95% CI, 6.8 to 11.3)
      • Men 11.9 events (95% CI, 9.6 to 14.4)
    • Cumulative incidence for recurrent VTE at 10 years
      • Women: 29% (95% CI, 20% to 38%)
      • Men: 41% (95% CI, 28% to 56%)
    • Overall recurrence rate, comparing men to women
      • Rate ratio 1.4 (95% CI, 1.3 to 1.6; P<0.001)
  • Distal DVT: Risk of recurrence
    • 1.9% (95% CI, 0.5% to 4.3%)
  • Proximal DVT: Risk of recurrence
    • 1.4 times the rate of recurrent VTE compared to pulmonary embolism (P=0.004)
  • Case fatality rate for recurrent VTE was 4% (95% CI, 2% to 6%)

CONCLUSION:

  • Men vs women: Authors calculated long-term mortality risks over a 10 year period
    • Men: Net long-term mortality benefit to continuing anticoagulation (1.64% risk of fatal recurrent VTE vs 1.32% risk of fatal major bleeding) due to greater recurrent VTE risk
    • Women: Net long-term benefit not found (1.16% risk of fatal recurrent VTE vs 1.32% risk of fatal major bleeding)
  • Determination of whether to continue anticoagulation treatment will depend on several factors
  • Because recurrence risk declines over time, the authors state

Our results suggest that patients who have not experienced a recurrence within two years of discontinuing anticoagulant treatment are unlikely to experience a net long term mortality benefit from restarting anticoagulation

Learn More – Primary Sources:

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

What impact does Pre-pregnancy BMI have on Venous Thromboembolism Risk?
What is the Risk for Venous Thromboembolism Following Cesarean Section?
When to Stop Anticoagulation Following a DVT or Pulmonary Embolus?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site